Efficacy and safety of eliapixant in endometriosis-associated pelvic pain: the randomized, placebo-controlled phase 2b SCHUMANN study

Abstract Background The SCHUMANN study evaluated the efficacy and safety of the selective P2 × 3 antagonist eliapixant in patients with endometriosis-associated pelvic pain (EAPP). Methods SCHUMANN was a randomized, placebo- and active comparator-controlled, double-blind to placebo and open-label to...

Volledige beschrijving

Bibliografische gegevens

Hoofdauteurs:	Susanne Parke, Kerstin Gude, Katrin Roth, Fabrizio Messina
Formaat:	Artigo
Taal:	Inglês
Gepubliceerd in:	BMC 2024-06-01
Reeks:	BMC Women's Health
Onderwerpen:	Endometriosis-associated pelvic pain Eliapixant P2X3 receptor antagonist Phase 2b clinical trial
Online toegang:	https://doi.org/10.1186/s12905-024-03188-8
Tags:	Voeg label toe Geen labels, Wees de eerste die dit record labelt!